Trusted Resources: News & Meetings
Latest announcements and gatherings
Years of Thyroid Monitoring Needed After MS Drug Alemtuzumab
Treatment with the multiple sclerosis (MS) drug alemtuzumab (Lemtrada, Genzyme/Sanofi) is associated with thyroid dysfunction and an increased risk of Graves disease that may have onset later than previously thought and therefore could require longer-term monitoring, according to results of one of the largest case series to date, spanning 20 years.
“Alemtuzumab is a highly effective therapy for relapsing-remitting MS, [with a] number needed to treat to benefit of five [and] number needed to treat for a serious adverse event of 148,” say Nadia Pariani, University of Cambridge Metabolic Research Laboratories, Institute of Metabolic Science, Addenbrooke’s Hospital, Cambridge, United Kingdom, and colleagues.
“However, the development of thyroid autoimmunity months or years after treatment is a frequent complication, requiring ongoing biochemical surveillance for at least 4 years after alemtuzumab therapy to detect and treat thyroid dysfunction promptly,” they note in their article published in the Journal of Clinical Endocrinology and Metabolism.
myBinderRelated Content
-
Hyperthyroidism and Your HeartHyperthyroidism occurs when your thyroid...
-
Barbra Sue Miller, MDBarbra S. Miller is the Co-Director of T...
-
Racial Disparities in Thyroid Surgery: Summary for the PublicBackground: Recent protests over police...
-
University of Pittsburgh Medical Center – Multidisciplinary Thyroid CenterUniversity of Pittsburgh Medical Center ...
-
Cancer Mortality Following Treatment for Adult HyperthyroidismContext: High-dose iodine 131 is the tr...
-
Hyperthyroidism Figurehttps://www.uptodate.com/contents/image?...
-
Hyperthyroidism and Graves’ DiseaseWhat is the Thyroid? The thyroid is a s...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Facebook
Google